GlaxoSmithKline (GSK) has presented an overview of its neuroscience portfolio and the company’s disease strategy to investors and analysts at a meeting in New York.
The portfolio spans 13 different areas, including Alzheimer’s disease, depression, schizophrenia and multiple sclerosis.
The company revealed that:
- More than 25 innovative compounds are in development, with 15 new mechanisms of action.
- Eight approvals, eight filings and nine key assets have started phase III trials so far in 2007.
- FDA filing of Promacta, a new oral treatment for short-term idiopathic thrombocytopenic purpura, will be submitted shortly.
Moncef Slaoui, GSK’s chairman of research and development (R&D), said: “GSK continues to make good progress with its pipeline and we have set out our vision in the area of neuroscience.
“Alongside vaccines, oncology and biopharmaceuticals, this is a key area for additional R&D investment and future growth for GSK.
“Diseases such as schizophrenia, Alzheimer’s and Parkinson’s disease present a chronic and ever-expanding burden to patients, caregivers and healthcare systems across the world.
“Every 72 seconds, a person is diagnosed with Alzheimer’s disease. The urgency to provide medical solutions for this and other neurological diseases has never been greater.”
Copyright © PA Business 2007